Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily
Version of Record online: 3 JUN 2013
© 2013 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Volume 15, Issue 1, pages 50–56, January 2014
How to Cite
Zorrilla, C., Wright, R., Osiyemi, O., Yasin, S., Baugh, B., Brown, K., Coate, B., Verboven, P., Mrus, J., Falcon, R. and Kakuda, T. (2014), Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily. HIV Medicine, 15: 50–56. doi: 10.1111/hiv.12047
- Issue online: 3 DEC 2013
- Version of Record online: 3 JUN 2013
- Manuscript Accepted: 12 APR 2013
- Janssen Services LLC
- 1Pharmacokinetics of darunavir once or twice daily during and after pregnancy. 3rd International Workshop on HIV Pediatrics. Rome, Italy, July 15–16, 2011. Poster P72., , et al.
- 9A comparison of the pharmacokinetics of darunavir, atazanavir and ritonavir during pregnancy and post-partum. 19th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, USA, March, 2012 [Poster 1013]., , et al.